BSECompany Update21 Aug 2026 · 21 Aug 2026, 03:38 pm

Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.

Aurobindo Pharma Ltd · 524804

✦ AI Summary▲ PositiveRegulatory

Aurobindo Pharma Ltd has completed a US FDA inspection at Auro Peptides Ltd, a subsidiary, with only one observation related to facility and equipment maintenance. The company has initiated corrective action and will submit a formal response within the stipulated timeline.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment7/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.

Attachments (1)

📄

22b0319d-27dd-4673-85fd-454bd91f4977.pdf

pdf

Download →
View document text
August 21, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Completion of US FDA Inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company. Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The United States Food and Drug Administration (US FDA) conducted a routine inspection at AuroPeptides Ltd, a manufacturer of Peptide APIs, located at Indrakaran Village, Kandi Mandal, Sangareddy District, Telangana - 502329, from 17th to 21st August, 2026. We are pleased to inform you that the inspection concluded with only one (1) observation, relating to facility and equipment maintenance. This observation does not pertain to data integrity or related GMP compliance. Corrective action was already initiated during the course of the inspection, and our formal response will be submitted within the stipulated timeline. This outcome reaffirms the Company's continued commitment to maintaining robust quality and compliance standards across its manufacturing facilities. The Company will keep the Stock Exchanges informed of any further developments in this regard, as required under the applicable regulations. Please take the above information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com